Summary: The number of oral antidiabetic medications has been growing steadily over the last decade, enabling type 2 diabetes therapy to be individualized. Currently six groups of oral antidiabetic medications are available in Poland: biguanides (metformin), sulfonylureas (gliclazide, glimepiride, glipizide, gliquidone), PPARg agonists (pioglitazone), a-glucosidase inhibitors (acarbose), dipeptidyl peptidase-4 inhibitors (sitagliptin, wildagliptin, saxagliptin, linagliptin), sodium glucose cotransporter 2 inhibitors (dapagliflozin, canagliflozin, empagliflozin). The paper describes the current role of each drug group and presents the most recent data on the cardiovascular safety and benefits of the newest medications.